Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...

In a region where the chronic disease is too often viewed as a normal part of life, one advocate is educating children to change that.

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Franciscan Health is offering residents an opportunity to stem the tide of prediabetes. Starting at 6 p.m. April 8, the ...

TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Biocon said that its wholly owned subsidiary, Biocon Biologics announced strategic collaboration agreement with Civica, Inc. to expand access, affordability of Insulin Aspart in the United States.

Adults with disabilities, especially moderate to severe, have a higher prevalence of diabetes than the general population in the United States.

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...